HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
Authors:
- Mary E. MolloyMMMary E. Molloy
- Wade H. AaronWAWade H. Aaron
- Manasi BarathMBManasi Barath
- Mabel C. BushMBMabel C. Bush
- Evan C. CallihanECEvan C. Callihan
- Kevin CarlinKCKevin Carlin
- Michael CreminMCMichael Cremin
- Thomas EvansTEThomas Evans
- Maria G. GuerreroMGMaria G. Guerrero
- Golzar HemmatiGHGolzar Hemmati
- Avneel S. HundalAHAvneel S. Hundal
- Llewelyn LaoLLLlewelyn Lao
Open Access
- 26 April 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 23 (9) , 1294-1304
Abstract
Delta-like ligand 3 (DLL3) is expressed in more than 70% of small cell lung cancers (SCLCs) and other neuroendocrine-derived tumor types. SCLC is highly aggressive, and limited therapeutic options lead to poor prognosis for patients. HPN328 is a trispecific T cell–activating construct (TriTAC) consisting of three binding domains: a CD3 binder for T-cell engagement, an albumin binder for half-life extension, and a DLL3 binder for tumor cell engagement. In vitro assays, rodent models, and non-human primates were used to assess the activity of HPN328. HPN328 induces potent dose-dependent killing of DLL3-expressing SCLC cell lines in vitro, concomitant with T-cell activation and cytokine release. In an NCI-H82 xenograft model with established tumors, HPN328 treatment led to T-cell recruitment and anti-tumor activity. In an immunocompetent mouse model expressing a human CD3ε epitope, mice previously treated with HPN328 withstood tumor rechallenge, demonstrating long-term anti-tumor immunity. When repeat doses were administered to cynomolgus monkeys, HPN328 was well tolerated up to 10 mg/kg. Pharmacodynamic changes, such as transient cytokine elevation, were observed, consistent with the expected mechanism of action of T-cell engagers. HPN328 exhibited linear pharmacokinetics in the given dose range with a serum half-life of 78 to 187 hours, supporting weekly or less frequent administration of HPN328 in humans. Preclinical and nonclinical characterization suggests that HPN328 is a highly efficacious, safe, and novel therapeutic candidate. A phase 1/2 clinical trial is currently underway testing safety and efficacy in patients with DLL3-expressing malignancies.Keywords
All Related Versions
Funding Information
- Harpoon Therapeutics
This publication has 32 references indexed in Scilit:
- Teclistamab: First ApprovalDrugs, 2022
- Tebentafusp: First ApprovalDrugs, 2022
- Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU StudyJournal of Thoracic Oncology, 2021
- P3.12-03 Targeting DLL3 with AMG 757, a BiTE® Antibody Construct, and AMG 119, a CAR-T, for the Treatment of SCLCJournal of Thoracic Oncology, 2018
- Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 studyThe Lancet Oncology, 2017
- Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?Journal of Thoracic Oncology, 2016
- Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case–control studiesInternational Journal of Cancer, 2011
- Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cellsLeukemia Research, 2009
- Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cellsMolecular Immunology, 2006
- T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody constructCancer Immunology, Immunotherapy, 2005